Anti-gd2 antibodies
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNai-Kong Cheung, Mahiuddin Ahmed, Hong Xu
Life of this patent
Estimating the term…
Abstract
In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
Claims43
1-36. (canceled)
A humanized or chimeric antibody or fragment thereof capable of binding to GD2, wherein the antibody or fragment thereof comprises any of the following:
- (i) a variable heavy chain domain of SEQ ID NO:
- 1 and a variable light chain domain of SEQ ID NO:2;
- (ii) a variable heavy chain domain of SEQ ID NO:3 and a variable light chain domain of SEQ ID NO:2;
- (iii) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:5;
- (iv) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:7;
- (v) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:5;
- (vi) a variable heavy chain domain of SEQ ID NO:9 and a variable light chain domain of SEQ ID NO:
- 10;
- and
- (vii) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:
- 5.
An isolated nucleic acid molecule encoding a humanized or chimeric antibody or fragment thereof capable of binding GD2, wherein the humanized or chimeric antibody or fragment thereof comprises any of the following:
- (i) a variable heavy chain domain of SEQ ID NO:
- 1 and a variable light chain domain of SEQ ID NO:2;
- (ii) a variable heavy chain domain of SEQ ID NO:3 and a variable light chain domain of SEQ ID NO:2;
- (iii) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:5;
- (iv) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:7;
- (v) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:5;
- (vi) a variable heavy chain domain of SEQ ID NO:9 and a variable light chain domain of SEQ ID NO:
- 10;
- (vii) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:
- 5;
- (viii) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:
- 7;
- and
- (ix) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:
- 7.
A method of treating or preventing a medical condition in the subject, comprising administering a therapeutically effective amount of a humanized or chimeric antibody or fragment thereof, wherein the humanized or chimeric antibody or fragment thereof comprises any of the following:
- (i) a variable heavy chain domain of SEQ ID NO:
- 1 and a variable light chain domain of SEQ ID NO:2;
- (ii) a variable heavy chain domain of SEQ ID NO:3 and a variable light chain domain of SEQ ID NO:2;
- (iii) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:5;
- (iv) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:7;
- (v) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:5;
- (vi) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:
- 7;
- (vii) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:
- 5;
- (viii) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:
- 7;
- and
- (ix) a variable heavy chain domain of SEQ ID NO:9 and a variable light chain domain of SEQ ID NO:
- 10.
A method of treating or preventing a medical condition in the subject, comprising administering a therapeutically effective amount of a nucleic acid molecule encoding a bispecific antibody having first and second antigen-binding sites, which first antigen-binding site comprises a light chain and a heavy chain of a humanized 3F8 antibody, wherein the humanized 3F8 antibody comprises any of the following:
- (i) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:5;
- (ii) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:5;
- (iii) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:5;
- (iv) a variable heavy chain domain of SEQ ID NO:9 and a variable light chain domain of SEQ ID NO:
- 10;
- (v) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:
- 7;
- (vi) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:
- 7;
- and
- (vii) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.